Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus KANAMYCIN SULFATE.
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus KANAMYCIN SULFATE.
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE vs KANAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of mRNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
None Documented
None Documented
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic